News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Is It Time to Screen for and Treat Early Multiple Myeloma?
Multiple myeloma (MM) is a blood cancer that evolves from the early precursor conditions of monoclonal gammopathy of undetermined significance (MGUS). This article discusses why early detection matters, who should be screened, and the need for precise risk stratification.
×
